GlassScriptPhysician profile
Matthew R Riebel
NPI 1376639385
$3,524.87
in general payments reported to CMS, 2019-2025
33 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $118 · 2021: $218 · 2022: $439 · 2023: $663 · 2024: $590 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $454.42 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $395.97 | 2019-2024 | Xtandi, Myrbetriq |
| Laborie Medical Technologies Corp. | $318.61 | 2025 | |
| Medtronic, INC. | $286.92 | 2021-2025 | Interstim |
| Urogen Pharma, INC. | $254.81 | 2021-2025 | Jelmyto |
| Pfizer INC. | $230.53 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $203.47 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $187.62 | 2021-2025 | Rezum Generator, General - Kidney Stone Disease |
| Janssen Biotech, INC. | $148.79 | 2019-2025 | Erleada |
| Abbvie INC. | $137.99 | 2023-2025 | |
| Urovant Sciences INC | $99.98 | 2022 | |
| Progenics Pharmaceuticals, INC. | $78.96 | 2023-2025 | Pylarify |
| Endo USA, INC. | $75.83 | 2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $74.48 | 2020-2024 | Xiaflex, Aveed |
| Myovant Sciences INC. | $53.83 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $52.79 | 2021 | |
| Olympus America INC. | $50.51 | 2023-2025 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $46.69 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $46.23 | 2024-2025 | |
| Immunitybio, INC. | $40.23 | 2024-2025 | |
| Teleflex LLC | $37.65 | 2024-2025 | Barrigel, Urolift |
| Amgen INC. | $34.22 | 2019 | |
| Procept Biorobotics Corporation | $29.17 | 2021-2022 | |
| Antares Pharma, INC. | $27.92 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Genzyme Corporation | $27.59 | 2022 | |
| Sun Pharmaceutical Industries INC. | $26.40 | 2025 | |
| Convatec INC. | $22.14 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2023 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $17.86 | 2022 | |
| Accord Healthcare, INC. | $14.88 | 2024 | |
| Verity Pharmaceuticals INC. | $14.42 | 2025 | Trelstar |
| Steris Corporation | $13.99 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$739.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Riebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.